Dihydroartemisinin restores the immunogenicity and enhances the anticancer immunosurveillance of cisplatin by activating the PERK/eIF2α pathway.
Yumei LiPei MaJingxia LiFeng WuMengfei GuoE ZhouSiwei SongSufei WangShuai ZhangYang JinPublished in: Cell & bioscience (2024)
We highlighted that dihydroartemisinin acts as an immunogenic cell death rescuer for cisplatin, activating anticancer immunosurveillance in a PERK/eIF2α-dependent manner and offering a strategy to enhance the anti-tumor efficacy of cisplatin in clinical practice.